Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries DOI Open Access
Margherita Sisto, Sabrina Lisi

Опубликована: Авг. 7, 2023

Interleukin (IL)-23 is a central proinflammatory cytokine with broad range of effects on immune responses. The pathological consequences excessive IL-23 signaling have been linked to its ability promote the production inflammatory mediators such as IL-17, IL-22 by stimulating differentiation and proliferation T helper type 17 (Th17 cells). Emerging evidence suggests potential pro-fibrotic role for in development chronic autoimmune diseases characterized intense fibrosis. In this review, we summarized biological features gathered recent research fibrotic conditions, which could provide theoretical basis clinical targeting drug development.

Язык: Английский

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications DOI
Zuber Khan, Sidharth Mehan, Ghanshyam Das Gupta

и другие.

Neuroscience, Год журнала: 2024, Номер 548, С. 9 - 26

Опубликована: Апрель 30, 2024

Язык: Английский

Процитировано

16

Association Between Diffusion Tensor Imaging Measurements and Cognitive Performances in People with Multiple Sclerosis: A Systematic Review and Meta-analysis DOI
Omid Mirmosayyeb, Mohammad Yazdan Panah, Saeed Vaheb

и другие.

Multiple Sclerosis and Related Disorders, Год журнала: 2025, Номер 94, С. 106261 - 106261

Опубликована: Янв. 6, 2025

Язык: Английский

Процитировано

1

Disruptions in cellular communication: Molecular interplay between glutamate/NMDA signalling and MAPK pathways in neurological disorders DOI
Sumedha Gupta, Abhishek Gupta, Sidharth Mehan

и другие.

Neuroscience, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

1

Navigating the Complexities of Neuronal Signaling and Targets in Neurological Disorders: From Pathology to Therapeutics DOI

Divya Choudhary,

Muhammad Imran Khan, Zuber Khan

и другие.

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177417 - 177417

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

1

Icariin prevents methylmercury-induced experimental neurotoxicity: Evidence from cerebrospinal fluid, blood plasma, brain samples, and in-silico investigations DOI Creative Commons

Sarthak Sharma,

Sidharth Mehan, Zuber Khan

и другие.

Heliyon, Год журнала: 2024, Номер 10(1), С. e24050 - e24050

Опубликована: Янв. 1, 2024

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that causes significant neurodegeneration. Methylmercury (MeHg) neurotoxin induces axonal neurodegeneration and motor nerve degeneration by destroying oligodendrocytes, degenerating white matter, inducing apoptosis, excitotoxicity, reducing myelin basic protein (MBP). This study examines the inhibition of SIRT-1 (silence information regulator 1), Nrf-2 (nuclear factor E2-related 2), HO-1 (heme oxygenase TDP-43 (TAR-DNA-binding 43) accumulation in context ALS, as well modulation these proteins icariin (15 30 mg/kg, orally), glycoside flavonoid with neuroprotective properties. Neuroprotective activates SIRT-1, Nrf-2, HO-1, mitigating inflammation neuronal injury disorders. In-vivo in-silico testing experimental ALS models confirmed efficacy modulating cellular targets. The addition sirtinol 10 an inhibitor helps determine effectiveness icariin. In this study, we also examined neurobehavioral, neurochemical, histopathological, LFB (Luxol fast blue) markers various biological samples, including Cerebrospinal fluid (CSF), blood plasma, brain homogenates (Cerebral Cortex, Hippocampus, Striatum, mid-brain, Cerebellum). These results demonstrate administration ameliorates mechanism underlying benefits likely related to regulating signaling pathways.

Язык: Английский

Процитировано

9

Microfluidics as diagnostic tools DOI
Avanthika Satish Kumar,

Sneha Venkatesalu,

Shanmugapriya Dilliyappan

и другие.

Clinica Chimica Acta, Год журнала: 2024, Номер 556, С. 117841 - 117841

Опубликована: Фев. 22, 2024

Язык: Английский

Процитировано

9

Guggulsterone Selectively Modulates STAT-3, mTOR, and PPAR-Gamma Signaling in a Methylmercury-Exposed Experimental Neurotoxicity: Evidence from CSF, Blood Plasma, and Brain Samples DOI
Sumit Kumar, Sidharth Mehan, Zuber Khan

и другие.

Molecular Neurobiology, Год журнала: 2024, Номер 61(8), С. 5161 - 5193

Опубликована: Янв. 3, 2024

Язык: Английский

Процитировано

7

Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations DOI
Swesha Chhabra, Sidharth Mehan, Zuber Khan

и другие.

Journal of Neuroimmunology, Год журнала: 2023, Номер 384, С. 578200 - 578200

Опубликована: Сен. 16, 2023

Язык: Английский

Процитировано

14

Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders DOI
Aditi Giri, Sidharth Mehan, Zuber Khan

и другие.

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2024, Номер 397(6), С. 3867 - 3895

Опубликована: Янв. 16, 2024

Язык: Английский

Процитировано

6

Association of Higher Mediterranean Diet Adherence With Lower Prevalence of Disability and Symptom Severity, Depression, Anxiety, Stress, Sleep Quality, Cognitive Impairment, and Physical Inactivity in Older Adults With Multiple Sclerosis DOI

Christina Tryfonos,

Eleni Pavlidou, Theofanis Vorvolakos

и другие.

Journal of Geriatric Psychiatry and Neurology, Год журнала: 2023, Номер 37(4), С. 318 - 331

Опубликована: Ноя. 29, 2023

A good nutritional status and healthy diets may decelerate disease disability symptom severity quality of life peoples with multiple sclerosis (MS). Mediterranean diet (MD) can prevent several chronic diseases, including neurodegenerative disease. This is an observational, cross-sectional study on 279 older adults MS, aiming to investigate the effects MD against aspects mental health. Qualified questionnaires were used assess severity, depression, anxiety, stress, sleep quality, cognitive status, physical activity, adherence. Multivariate analysis showed that enhanced adherence was independently associated lower prevalence ( P = .0019), depression .0201), anxiety .0287), perceived stress .0021), inadequate .0033), impairment .0018) inactivity .0028). Adopting ameliorate health disturbances in MS. Future public policies should inform MS for favorable impacts improving comorbidities.

Язык: Английский

Процитировано

10